Effect of Empagliflozin Beyond Glycemic Control: Cardiovascular Benefit in Patients with Type 2 Diabetes and Established Cardiovascular Disease

Submitted by Ana Quininha (ana.quininha@chlc.min-saude.pt) on 2021-02-05T16:45:08Z No. of bitstreams: 1 RPC 2019 721.pdf: 1327108 bytes, checksum: e750a5ed0fc728132c3345f4ec35e04d (MD5)

Detalhes bibliográficos
Autor principal: Monteiro, P (author)
Outros Autores: Aguiar, C (author), Matos, P (author), Silva-Nunes, J (author), Birne, R (author), Branco, P (author), Calado, J (author), Melo, M (author), Polónia, J (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Benzhydryl Compounds
Blood Glucose
Glucosides
Humans
Sodium-Glucose Transporter 2 Inhibitors
Cardiovascular Diseases
Diabetes Mellitus, Type 2
HCC END
HCC NEF
Texto completo:http://hdl.handle.net/10400.17/3563
País:Brasil
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3563

Texto Completo

http://hdl.handle.net/10400.17/3563

Registros relacionados